Memorial Hermann Health System
Houston, Texas, 77007-1708, United States
NCT Number: NCT06659965
The goal of this target trial emulation is to evaluate the impact of intravenous (IV) methocarbamol on postoperative pain and opioid use in adults undergoing elective spine surgery. The main questions it aims to answer are:
* Does IV methocarbamol reduce pain in the 6 hours following surgery? * Does IV methocarbamol decrease the need for opioid pain medications in the same period?
Participants who receive IV methocarbamol as part of their routine postoperative care will have their pain scores and opioid consumption tracked for 6 hours after treatment. Pain levels will be measured using standard assessments, and opioid use will be quantified in oral morphine equivalents.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Houston, Texas, 77007-1708, United States
The IMAPSS study is a target trial emulation evaluating the effect of intravenous (IV) methocarbamol on postoperative pain management and opioid consumption in adult patients undergoing elective spine surgery. The study employs a target trial emulation design to simulate the conditions of a randomized controlled trial using observational data extracted from electronic medical records. The main focus is to determine if administering IV methocarbamol within two hours after surgery reduces postoperative pain scores and opioid use.
Patients will be tracked from the point of their first recorded pain score in the Post-Anesthesia Care Unit (PACU) after surgery to assess for treatment assignment eligibility. Data will be collected at 15-minute intervals, which corresponds to the standard assessment frequency in Phase I PACU care, for up to 12 hours postoperatively for each patient. The primary analysis will use time-varying propensity score matching (TV-PSM) to control for baseline and time-varying confounders. Pain levels will be measured using a time-weighted average (TWA) of pain scores, and opioid consumption will be quantified in oral morphine equivalents (OME).
The primary analysis will utilize TV-PSM, with propensity scores estimated through a Cox proportional hazards model. Matching will create balanced treatment groups at each 15-minute interval. Generalized estimating equations (GEE) will then estimate the effect of IV methocarbamol on the primary outcome (TWA pain) and secondary outcome (cumulative OME) over a 6-hour postoperative period. As a sensitivity analysis, a marginal structural model (MSM) using inverse probability weighting (IPW) will assess the robustness of the findings to the time-varying confounder adjustment.
This study's findings will aim to inform evidence-based recommendations for postoperative pain management and opioid-sparing strategies, potentially providing safer alternatives to conventional opioid-based regimens.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
Other names: Robaxin
Time frame: 6 hours after treatment assignment
The primary outcome of this study is the Time-Weighted Average (TWA) pain score measured over the 6-hour period following treatment assignment. Pain scores are collected using a standardized numerical pain rating scale, ranging from 0 (no pain) to 10 (worst possible pain). These scores are assessed in 15-minute intervals, the standard frequency for Phase I PACU assessments, throughout the 6-hour follow-up period. The TWA pain score is calculated by averaging these pain ratings, giving greater weight to scores recorded more frequently or for longer periods. This method provides a comprehensive summary of the patient's pain experience over the observed time frame, accounting for fluctuations in pain intensity during recovery. A lower TWA score indicates better pain control and a potentially greater effect of the intervention.
Time frame: 6 hours after treatment assignment
The secondary outcome of this study is the cumulative opioid use measured in Oral Morphine Equivalents (OME) over the 6-hour period following treatment assignment. Opioid doses administered during this timeframe are converted into OME to standardize and compare the total amount of opioids used, accounting for the specific medication, dose, and route of administration. Data on opioid administration are assessed in 15-minute intervals, aligned with standard PACU assessment practices. The cumulative OME reflects the total opioid exposure a patient received, providing a quantitative measure of opioid consumption and its potential reduction with the intervention. Lower cumulative OME values suggest more effective pain management with fewer opioids, indicating the potential benefits of non-opioid alternatives.
The University of Texas Health Science Center, Houston
Other
Acronym: IMAPSS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686523
Acute Post Operative Pain, Neurologic Manifestations
Pathum Thani, Changwat Pathum Thani, Thailand
View Trial DetailsNCT06917807
Acute Post Operative Pain, Femoral Fractures
Cairo, Abassya, Egypt
View Trial DetailsNCT06307106
Acute Pain, Acute Post Operative Pain
Zagazig, zagazig, Egypt
View Trial DetailsNCT05074056
Acute Post Operative Pain, Adenotonsillar Hypertrophy
St Louis, Missouri, United States
View Trial Details